

Journal of the Neurological Sciences 163 (1999) 94-98



Consensus statement on the diagnosis of multiple system atrophy

S. Gilman^{a,*}, P.A. Low^b, N. Quinn^c, A. Albanese^d, Y. Ben-Shlomo^e, C.J. Fowler^c, H. Kaufmann^f, T. Klockgether^g, A.E. Lang^h, P.L. Lantosⁱ, I. Litvan^j, C.J. Mathias^k, E. Oliver^j, D. Robertson¹, I. Schatz^m, G.K. Wenningⁿ

^aDepartment of Neurology, University of Michigan Medical Center, 1500 E. Medical Center Drive/1914 TC, Ann Arbor, MI 48109-0316, USA

^bDepartment of Neurology, Mayo Clinic, 200 First Avenue, SW, Rochester, MN 55905, USA

^cDepartment of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK

^dDepartment of Neurology, Universita Cattolica, Istituto di Neurologia, Largo A. Genelli 8, 00168 Rome, Italy

^eDepartment of Social Medicine, Canynge Hall, Whiteladies Road, Clifton, Bristol BS8 2P, UK

^fDepartment of Neurology, Mt. Sinai Medical Center, 5 East 98th Street, New York, NY 10029, USA

^gDepartment of Neurology, University of Bonn, 25 Sigmund Freud Street, 53105 Bonn, Germany

^hDepartment of Neurology, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, MP11-304, Canada

¹Department of Neuropathology, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK

ⁱNIH-NINDS, Federal Building, 7550 Wisconsin Avenue, Bethesda, MD 20892, USA

^kDepartment of Neurovascular Medicine, Imperial College School of Medicine at St. Mary's, Pickering Unit, St. Mary's Hospital, Praed Street,

London W2 1NY, UK

¹Departments of Pharmacology and Neurology, Vanderbilt University, 1161 21st Avenue, S. AA3228 MCN, Nashville, TN 37232-2195, USA

^mDepartment of Medicine, University of Hawaii at Manoa, 1356 Lusitania Street, Honolulu, HI 96813, USA

ⁿUniversitaets-Klinik, fur Neurologie, Anichstrasse 35, A-6020 Innsbruck, Austria

Received 1 July 1998; accepted 10 August 1998

Abstract

We report the results of a consensus conference on the diagnosis of multiple system atrophy (MSA). We describe the clinical features of the disease, which include four domains: autonomic failure/urinary dysfunction, parkinsonism and cerebellar ataxia, and corticospinal dysfunction. We set criteria to define the relative importance of these features. The diagnosis of possible MSA requires one criterion plus two features from separate other domains. The diagnosis of probable MSA requires the criterion for autonomic failure/urinary dysfunction plus poorly levodopa responsive parkinsonism or cerebellar ataxia. The diagnosis of definite MSA requires pathological confirmation. © 1999 Published by Elsevier Science B.V. All rights reserved.

Keywords: Multiple system atrophy; Parkinsonism; Cerebellar ataxia; Autonomic insufficiency; Urinary dysfunction; Glial cytoplasmic inclusion

1. Introduction

Multiple system atrophy (MSA), a progressive neurodegenerative disease of undetermined etiology, occurs sporadically and causes parkinsonism and cerebellar, autonomic, urinary, and pyramidal dysfunction in many combinations [1,3,7,21]. The disease affects both sexes, usually beginning in middle age and progressing over intervals of 1-18 years, with a median survival of 9.3 years from the first symptom [9,26]. The parkinsonian features include bradykinesia with rigidity, postural instability, hypokinetic speech, and often tremor, usually with a poor or unsustained response to chronic levodopa therapy. The cerebellar dysfunction consists of ataxia of gait, limb movements and speech, and disorders of extraocular movements [6]. Autonomic insufficiency results in

^{*}Corresponding author. Tel.: +1-734-936-9070; fax: +1-734-763-5059; e-mail: sgilman@umich.edu

Table 1

Clinical domains, features and criteria used in the diagnosis of MSA. A feature (A) is a characteristic of the disease and a criterion (B) is a defining feature or composite of features required for diagnosis I. Autonomic and urinary dysfunction A. Autonomic and urinary features 1. Orthostatic hypotension (by 20 mmHg systolic or 10 mmHg diastolic) 2. Urinary incontinence or incomplete bladder emptying B. Criterion for autonomic failure or urinary dysfunction in MSA Orthostatic fall in blood pressure (by 30 mmHg systolic or 15 mmHg diastolic) or urinary incontinence (persistent, involuntary partial or total bladder emptying, accompanied by erectile dysfunction in men) or both II. Parkinsonism A. Parkinsonian features 1. Bradykinesia (slowness of voluntary movement with progressive reduction in speed and amplitude during repetitive actions) 2. Rigidity 3. Postural instability (not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction) 4. Tremor (postural, resting or both) B. Criterion for parkinsonism in MSA Bradykinesia plus at least one of items 2 to 4 III. Cerebellar dysfunction A. Cerebellar features 1. Gait ataxia (wide based stance with steps of irregular length and direction) 2. Ataxic dysarthria 3. Limb ataxia 4. Sustained gaze-evoked nystagmus B. Criterion for cerebellar dysfunction in MSA Gait ataxia plus at least one of items 2 to 4 IV. Corticospinal tract dysfunction A. Corticospinal tract features 1. Extensor plantar responses with hyperreflexia B. Corticospinal tract dysfunction in MSA: no corticospinal tract features are used in defining the diagnosis of MSA

orthostatic hypotension, often with an inadequate heart rate response to standing, male erectile dysfunction (MED), constipation, and decreased sweating [18,22]. Urinary symptoms include urgency, frequency, nocturia, incomplete bladder emptying, and incontinence [2]. The diagnosis of MSA requires primarily clinical assessment, however, a number of laboratory tests may help to support the diagnosis.

The neuropathological changes consist of a high density of glial cytoplasmic inclusions (GCIs) in association with degenerative changes in some or all of the following structures: putamen, caudate nucleus, globus pallidus, substantia nigra, locus ceruleus, inferior olives, pontine nuclei, cerebellar Purkinje cells, autonomic nuclei of the brainstem, and the intermediolateral cell columns and Onufs nucleus in the spinal cord [4,12]. GCIs are ubiquitin-, tau- and a-synuclein-positive oligodendroglial inclusions [12].

Some efforts have been made to establish diagnostic criteria [3], but no consistent detailed guidelines have been developed. Accordingly, a consensus conference was convened on April 23 and 24, 1998 in Minneapolis, Minnesota, cosponsored by the American Autonomic Society and the American Academy of Neurology. The goal of the conference was to develop guidelines for the diagnosis of MSA. We achieved consensus on the items listed below and shown in Tables 1–3. These guidelines have not yet been validated, and will almost certainly

Diagnostic categories of MSA. The features and criteria for each clinical domain are shown in Table 1

- I. Possible MSA: one criterion plus two features from separate other domains. When the criterion is parkinsonism, a poor levodopa response qualifies as one feature (hence only one additional feature is required).
- II. Probable MSA: criterion for autonomic failure/urinary dysfunction plus poorly levodopa responsive parkinsonism or cerebellar dysfunction.

III. Definite MSA: pathologically confirmed by the presence of a high density of glial cytoplasmic inclusions in association with a combination of degenerative changes in the nigrostriatal and olivopontocerebellar pathways.

Table 2

Table 3					
Exclusion	criteria	for	the	diagnosis	of MSA

-	
I.	History
	Symptomatic onset under 30 years of age
	Family history of a similar disorder
	Systemic diseases or other identifiable causes for features listed in Table 1
	Hallucinations unrelated to medication
II	. Physical examination
	DSM criteria for dementia
	Prominent slowing of vertical saccades or vertical supranuclear gaze palsy ^a
	Evidence of focal cortical dysfunction such as aphasia, alien limb syndrome, and parietal dysfunction
Π	L Laboratory investigation

Metabolic, molecular genetic and imaging evidence of an alternative cause of features listed in Table 1

^aIn practice, MSA is most frequently confused with Parkinson's disease or progressive supranuclear palsy (PSP) [14]. Mild limitation of upward gaze alone is nonspecific, whereas a prominent (>50%) limitation of upward gaze or any limitation of downward gaze suggests PSP [13]. Before the onset of vertical gaze limitation, a clinically obvious slowing of voluntary vertical saccades is usually easily detectable in PSP and assists in the early differentiation of these two disorders [13].

require further modification in the light of future experience.

2. Clinical domains

2.1. Autonomic and urinary dysfunction

Orthostatic hypotension (OH) may indicate autonomic failure and can be asymptomatic or symptomatic. When symptomatic, it typically occurs after the onset of MED and urinary symptoms. Symptoms of OH result from cerebral hypoperfusion, and syncope may occur. The consensus conference determined that the clinical diagnosis of probable MSA requires a reduction of systolic blood pressure by at least 30 mmHg or of diastolic blood pressure by at least 15 mmHg within 3 min of standing from the recumbent position. Frequently this is accompanied by an inadequate increase in heart rate (less than 10 beats/min). We note that this is a more pronounced degree of OH than established previously [3]. MED appears early and affects virtually all male patients with MSA, but the symptom has low specificity. Urinary frequency, urgency, incontinence or incomplete bladder emptying also occur early and commonly.

2.2. Parkinsonism

The majority of MSA patients develop parkinsonian features at some stage of the disorder. All these patients have bradykinesia, rigidity, postural instability, and tremor also often occurs. The tremor is usually irregular and postural, often incorporating myoclonus. A classical pillrolling parkinsonian rest tremor is uncommon. The parkinsonism in MSA can be asymmetric. The dysarthria is mainly hypokinetic, often mixed with other components [10]. The parkinsonian features usually respond poorly to chronic levodopa therapy, however, up to 30% of patients show a clinically significant response to levodopa therapy

at some time in the course, but the response is usually sustained for less than 5 years [8,20,26]. These are the most challenging patients for accurate diagnosis.

2.3. Cerebellar dysfunction

Ataxia of gait, the most common cerebellar feature of MSA, often occurs accompanied by dysarthria, limb ataxia, and sometimes gaze-evoked nystagmus and ocular dysmetria. A common finding is saccadic pursuit movements. The dysarthria in patients with predominantly cerebellar dysfunction is mainly ataxic, often mixed with other components [10].

2.4. Corticospinal dysfunction

Extensor plantar responses with hyperreflexia occur in about 50% of MSA patients. Corticospinal signs can contribute to the diagnosis, but are less important than abnormalities in the other domains.

3. Response to levodopa

Levodopa responsiveness should be tested by administering escalating doses (with a peripheral decarboxylase inhibitor) over a 3-month period up to at least 1 g/day (if necessary and if tolerated). A positive response is defined as clinically significant improvement. This should be demonstrated by objective evidence such as an improvement of 30% or more on part III (motor examination) of the Unified Parkinson's Disease Rating Scale [5].

4. Laboratory investigations

Autonomic function tests, sphincter electromyography (EMG), and neuroimaging may be used to support the diagnosis, and neuroimaging is helpful in excluding other conditions. The abnormalities described below have been defined principally in clinically well-established cases rather than in the early stages of the disease. In the early stages, the tests may give equivocal results. We consider it premature to incorporate laboratory results into the entirely clinical guidelines that we established, but envisage the future development of 'Laboratory Supported' diagnostic categories.

Assessment of autonomic function can be assisted by a comprehensive battery that evaluates the distribution and severity of sudomotor, cardiovagal and sympathetic adrenergic deficits [15,17]. Autonomic function tests may help separate MSA from Parkinson's disease and from the idiopathic cerebellar degenerations [22].

Sphincter EMG can be useful in the diagnosis of MSA. Analysis of individual motor unit potentials recorded from the external anal sphincter usually shows changes indicating chronic reinnervation, with markedly prolonged motor units [2,19].

Magnetic resonance imaging (MRI) can assist the evaluation by detecting abnormalities of striatum, cerebellum, and brainstem, but can be normal in up to 20% of cases [23]. Striatal abnormalities may include putaminal atrophy, slit-like signal change at the posterolateral putaminal margin, and hypointensity of the putamen relative to the globus pallidus [11]. Infratentorial abnormalities include cerebellar and pontine atrophy, and signal change in the pons and middle cerebellar peduncles [25]. Studies are in progress to evaluate the utility of magnetic resonance spectroscopy, positron emission tomography and single photon emission tomography.

5. Diagnostic categories

We established three diagnostic categories reflecting differing levels of certainty: definite, probable and possible. The diagnosis of definite MSA can only be made after neuropathological examination of the central nervous system revealing the characteristic density and distribution of GCIs and degenerative changes outlined above. The diagnosis of probable or possible MSA can be made utilizing different combinations of clinical domains, criteria and features, as indicated in Tables 1 and 2. Exclusion criteria are shown in Table 3.

6. Terminology

MSA is a distinct clinicopathological entity. The term should not be used to describe other neurodegenerative diseases affecting multiple systems. The use of confusing terms such as 'multisystem degeneration' for MSA is inappropriate and now should be discouraged. We recommend designating patients as having MSA-P if parkinsonian features predominate or MSA-C if cerebellar features predominate [16,24]. These terms are intended to replace the striatonigral degeneration (SND) and sporadic olivopontocerebellar atrophy (sOPCA) types of MSA, respectively. The term Shy Drager syndrome has been widely misused, and is no longer useful.

Acknowledgements

This conference was supported in part by the Office of Rare Diseases and the National Institute of Neurological Disorders and Stroke, National Institutes of Health; Glaxo Wellcome, Inc.; Hoechst Marion Roussell; and Roberts Pharmaceutical Corporation.

References

- [1] Albanese A, Colosimo C, Bentivoglio AR, Fenici R, Melillo G, Colosimo C, Tonali P. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry 1995;59:144–51.
- [2] Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994;151:1336–41.
- [3] Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996;46:1470.
- [4] Daniel SE. The neuropathology and neurochemistry of multiple system atrophy. In: Bannister R, Mathias CJ, editors. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. Oxford: Oxford University Press, 1992:564–585.
- [5] Fahn S, Elton R. Unified Parkinson's disease rating scale committee: unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne I, editors. Recent developments in Parkinson's disease. New York: Macmillan, 1987:153–164.
- [6] Gilman S. Multiple system atrophy. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders, 3rd edn. Baltimore: Williams and Wilkins, 1998:245–262.
- [7] Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969;32:28–34.
- [8] Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992;55:1009–13.
- [9] Klockgether T, Lüdtke R, Kramer B, Abele M, Bürk K, Schöls L, Riess O, Laccone F, Boesch S, Lopes-Cendes I, Brice A, Inzelberg R, Zilber N, Dichgans J. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 1998;121:589–600.
- [10] Kluin KJ, Gilman S, Lohman M, Junck L. Characteristics of the dysarthria of multiple system atrophy. Arch Neurol 1996;53:545–8.
- [11] Lang AE, Curran T, Provias J, Bergeron C. Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. Can J Neurol Sci 1994;21:311–8.
- [12] Lantos PL. Multiple system atrophy. Brain Pathol 1997;7:1293-7.
- [13] Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz C, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn N, Tolosa E, Zee DS. NINDS-SPSP clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;47:1–9.
- [14] Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ,

McKee A, Jellinger K, Lai EC, Brandel J-P, Verny M, Chaudhuri KR, Pearce RKB, Agid Y. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997;54:937–44.

- [15] Low PA. The composite autonomic scoring scale for the laboratory quantitation of generalized autonomic failure. Mayo Clin Proc 1993;68:748–52.
- [16] Mathias CJ. Autonomic dysfunction. Br J Hosp Med 1987;38:238– 43.
- [17] Mathias CJ, Bannister R. Investigation of autonomic disorders. In: Bannister R, Mathias CJ, editors. Autonomic failure. A textbook of clinical disorders of the autonomic nervous system, 3rd edn. Oxford: Oxford University Press, 1992:255–290.
- [18] Mathias CJ, Williams AC. The Shy Drager syndrome (and multiple system atrophy). In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: WB Saunders, 1994:743–768.
- [19] Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997;20:1396–403.
- [20] Parati EA, Fetoni V, Geminiani GC, Soliveri P, Giovannini P, Testa D, Genitrini S, Caraceni T, Girotti F. Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol 1993;16:139–44.

- [21] Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, editors. Movement disorders 3. London: Butterworths, 1996:262–281.
- [22] Sandroni P, Ahlskog JE, Fealey RD, Low PA. Autonomic involvement in extrapyramidal and cerebellar disorders. Clin Auton Res 1991;1:147–55.
- [23] Schrag A, Kingsley D, Phatouros C, Mathias CJ, Lees AJ, Daniel SE, Quinn NP. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998:in press.
- [24] Schulz JB, Klockgether T, Petersen D, Jauch M, Muller-Schauenburg W, Spieker S, Voigt K, Dichgans J. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994;57:1047–56.
- [25] Testa D, Savoiardo M, Fetoni V, Strada L, Palazzini E, Bertulezzi G, Girotti F. Multiple system atrophy. Clinical and MR observations on 42 cases. Ital J Neuro Sci 1993;14:211–6.
- [26] Wenning GK, Ben-Shlomo Y, Magalaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835–45.